Influence of Acrylic Resin Polymerization Methods on Residual Monomer Release and Porosity

Polymerization methods of acrylic resins have considerable effect on physical and mechanical properties like release monomer and porosity. The aim of this study was to investigate the release of residual monomer and porosity for acrylic denture base materials processed by different polymerization methods (heat and pour cured). Ten specimens were fabricated for each test. For release monomer test the samples were analyzed using gas chromatography with a flame ionization detector and for porosity test it was calculated by measurement of the specimen weight before its immersion in water and 7 days following immersion in water. Student t- test was performed to study the differences between the mean ratio of release monomer and porosity in heat-cured and pour-cured acrylic resin. The statistical analysis indicated highly significant differences in the mean rate of release monomer and porosity between pour-cured and heat-cured acrylic resin (P<0.001). As a conclusion, pour-cured acrylic processing method was significantly higher than heat-cured one in both residual monomer content and porosity

Liposomal phytohemagglutinin: In vivo T-cell activator as a novel pan-cancer immunotherapy

Immunotherapy is an attractive approach for treating cancer. T-cell engagers (TCEs) are a type of immunotherapy that are highly efficacious; however, they are challenged by weak T-cell activation and short persistence. Therefore, alternative solutions to induce greater activation and persistence of T cells during TCE immunotherapy is needed. Methods to activate T cells include the use of lectins, such as phytohemagglutinin (PHA). PHA has not been used to activate T cells in vivo, for immunotherapy, due to its biological instability and toxicity. An approach to overcome the limitations of PHA while also preserving its function is needed. In this study, we report a liposomal PHA which increased PHA stability, reduced toxicity and performed as an immunotherapeutic that is able to activate T cells for the use in future cancer immunotherapies to circumvent current obstacles in immunosuppression and T-cell exhaustion